Detection of new atrial fibrillation in patients with cardiac implanted electronic devices and factors associated with transition to higher device-detected atrial fibrillation burden
Jazyk angličtina Země Spojené státy americké Médium print-electronic
Typ dokumentu časopisecké články, multicentrická studie, pozorovací studie
PubMed
29122724
DOI
10.1016/j.hrthm.2017.11.007
PII: S1547-5271(17)31321-8
Knihovny.cz E-zdroje
- Klíčová slova
- Anticoagulants, Atrial fibrillation, Atrial fibrillation burden, Cardioverter-defibrillator, Pacemaker, Stroke,
- MeSH
- časové faktory MeSH
- cévní mozková příhoda diagnóza epidemiologie etiologie MeSH
- defibrilátory implantabilní * MeSH
- elektrofyziologické techniky kardiologické metody MeSH
- fibrilace síní diagnóza epidemiologie terapie MeSH
- hodnocení rizik metody MeSH
- incidence MeSH
- lidé MeSH
- míra přežití trendy MeSH
- následné studie MeSH
- prospektivní studie MeSH
- reprodukovatelnost výsledků MeSH
- rizikové faktory MeSH
- senioři MeSH
- Check Tag
- lidé MeSH
- mužské pohlaví MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- multicentrická studie MeSH
- pozorovací studie MeSH
- Geografické názvy
- Evropa epidemiologie MeSH
BACKGROUND: In patients with cardiac implanted electronic devices, detection of new atrial fibrillation (AF) is associated with an increased risk of stroke. OBJECTIVE: To characterize daily AF burden at first detection and the rate of temporal transition to higher device-detected AF burden. METHODS: A pooled analysis of data from 3 prospective projects was analyzed, and 6580 patients (mean age 68 ± 12 years, 72% male) with no history of AF and no use of anticoagulants at baseline were identified. Various thresholds of daily AF burden (5 minutes and 1, 6, 12, and 23 hours) were analyzed. RESULTS: Among the study population of 6580 patients, a new AF, with an AF burden of ≥5 minutes, was detected in 2244 patients (34%) during a follow-up period of 2.4 ± 1.7 years. Among these patients, 1091 (49.8%) transitioned to a higher AF-burden threshold during follow-up. A higher duration of daily AF burden manifest at first detection and CHADS2 score ≥2 were associated with faster transition to a subsequent higher burden. Approximately 24% of patients transitioned from a lower threshold to a daily AF burden of ≥23 hours during follow-up. CONCLUSION: More than one-third of patients with no history of AF developed device-detected AF, with attainment of different thresholds of daily AF burden over time. Continuous long-term monitoring, especially when the initial detection corresponds to a higher daily AF burden and the CHADS2 score is ≥2, could support timely clinical decisions on anticoagulation by capturing transitions to higher AF-burden thresholds.
Department of Internal Medicine Cardiology University Hospital Brno Brno Czech Republic
Hackensak University Medical Center Hackensack New Jersey
Isar Heart Center Munich Munich Germany
Medtronic Bakken Research Center Maastricht The Netherlands
Medtronic EMEA Regional Clinical Center Rome Italy
Medtronic Minneapolis Minnesota
Citace poskytuje Crossref.org
